Domainex and Ark Therapeutics extend drug discovery agreement
Domainex a UK-based provider of drug discovery systems, has extended its research agreement with Ark Therapeutics Group and will continue to provide Ark with hit-finding and lead optimisation services for drug discovery against therapeutic targets nominated by the company.
Domainex a UK-based provider of drug discovery systems, has extended its research agreement with Ark Therapeutics Group and will continue to provide Ark with hit-finding and lead optimisation services for drug discovery against therapeutic targets nominated by the company.
The two firms have been working closely for several years, successfully combining Domainex's capabilities in drug design and lead optimisation with Ark's disease and molecular biology expertise.
Finland and London-based Ark's main areas of interest are vascular disease, wound care and cancer.
Dr Trevor Perrior, research director of Domainex, said: "We look forward to taking these programmes to the next stage of their development, with the aim of delivering important new treatments for major life-threatening diseases."
